J Gastroenterol:胰管闭塞对接受新辅助治疗的胰头癌患者术后转归的影响

2024-09-27 xuyihan MedSci原创 发表于上海

胰腺癌预后极差,在美国统计的所有癌症中,胰腺癌的5年生存率最低(12%)。胰管闭塞可能与外分泌功能不全相关的营养不良导致的术后不良预后有关。

胰腺癌预后极差,在美国统计的所有癌症中,胰腺癌的5年生存率最低(12%)。胰腺切除术仍然是唯一的治愈方法,但由于其侵袭性高,存在术后胰瘘(POPF)、胃排空延迟(DGE)和术后出血(PPH)的风险,且与较高的术后早期复发率(79%)相关。通过识别新的预后指标来指导临床决策,可以改善术后结局。

近年来,新辅助治疗(NAT)已成为胰腺癌的主流治疗方法,并被证实可延长患者生存期。当肿瘤引起导管闭塞导致外分泌功能不全(PEI)相关营养不良时,胰头癌预后较差;然而,胰管闭塞对胰腺癌患者的影响此前尚未明确。这项研究探讨了胰管闭塞对接受NAT的胰头癌患者营养状况、身体成分和术后结局的影响。

2015-2022年,136例胰头癌患者在接受NAT后接受胰十二指肠切除术(PD)。比较阻断组(n=78)和非阻断组(n=58,其中分别有61例和44例患者最终行PD)的营养指标、人体测量学指标[体质量指数(BMI)、白蛋白、预后营养指数(PNI)、格拉斯哥预后评分、腰肌指数、皮下脂肪组织指数(SATI)和内脏脂肪组织指数]和术后结局。

在PD队列中,阻断组的NAT后BMI、PNI和SATI显著较低。阻断组主胰管明显增大,胰腺实质明显减小,胰管实质比明显增大,且这些形态学参数与NAT后营养指标和人体测量学指标显著相关。多因素分析显示,胰管阻断是影响患者术后3年总生存率和无复发生存率的独立危险因素,胰管阻断是影响患者术后3年总生存率和无复发生存率的独立危险因素。

 

这项研究的结果表明,胰管闭塞可能与外分泌功能不全相关的营养不良导致的术后不良预后有关。

 

原文出处:

Hidaka Y, Tanoue S, Ayukawa T, Takumi K, Noguchi H, Higashi M, Idichi T, Kawasaki Y, Kurahara H, Mataki Y, Ohtsuka T, Koriyama C. Impact of pancreatic ductal occlusion on postoperative outcomes in pancreatic head cancer patients undergoing neoadjuvant therapy. J Gastroenterol. 2024 Sep;59(9):858-868. doi: 10.1007/s00535-024-02125-8. Epub 2024 Jun 20. PMID: 38900299; PMCID: PMC11338973.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2228053, encodeId=d0452228053d7, content=预后极差,在美国统计的所有癌症中,胰腺癌的5年生存率最低(12%), beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0ad1894147, createdName=ms1907128386112981, createdTime=Fri Sep 27 21:39:13 CST 2024, time=2024-09-27, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2228046, encodeId=8090222804644, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Sep 27 20:58:00 CST 2024, time=2024-09-27, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2228066, encodeId=662922280668f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Sep 27 22:43:23 CST 2024, time=2024-09-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2228063, encodeId=0cfc222806344, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Fri Sep 27 22:15:46 CST 2024, time=2024-09-27, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2228095, encodeId=1221222809552, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Fri Sep 27 23:54:40 CST 2024, time=2024-09-27, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2228015, encodeId=378c2228015ae, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a> <a href='/topic/show?id=d524119613d4' target=_blank style='color:#2F92EE;'>#胰管闭塞#</a> <a href='/topic/show?id=c03511961492' target=_blank style='color:#2F92EE;'>#术后转归#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=119614, encryptionId=c03511961492, topicName=术后转归), TopicDto(id=119613, encryptionId=d524119613d4, topicName=胰管闭塞), TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cade5395722, createdName=梅斯管理员, createdTime=Fri Sep 27 16:24:58 CST 2024, time=2024-09-27, status=1, ipAttribution=上海)]
    2024-09-27 ms1907128386112981 来自河北省

    预后极差,在美国统计的所有癌症中,胰腺癌的5年生存率最低(12%)

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2228053, encodeId=d0452228053d7, content=预后极差,在美国统计的所有癌症中,胰腺癌的5年生存率最低(12%), beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0ad1894147, createdName=ms1907128386112981, createdTime=Fri Sep 27 21:39:13 CST 2024, time=2024-09-27, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2228046, encodeId=8090222804644, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Sep 27 20:58:00 CST 2024, time=2024-09-27, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2228066, encodeId=662922280668f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Sep 27 22:43:23 CST 2024, time=2024-09-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2228063, encodeId=0cfc222806344, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Fri Sep 27 22:15:46 CST 2024, time=2024-09-27, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2228095, encodeId=1221222809552, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Fri Sep 27 23:54:40 CST 2024, time=2024-09-27, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2228015, encodeId=378c2228015ae, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a> <a href='/topic/show?id=d524119613d4' target=_blank style='color:#2F92EE;'>#胰管闭塞#</a> <a href='/topic/show?id=c03511961492' target=_blank style='color:#2F92EE;'>#术后转归#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=119614, encryptionId=c03511961492, topicName=术后转归), TopicDto(id=119613, encryptionId=d524119613d4, topicName=胰管闭塞), TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cade5395722, createdName=梅斯管理员, createdTime=Fri Sep 27 16:24:58 CST 2024, time=2024-09-27, status=1, ipAttribution=上海)]
    2024-09-27 医鸣惊人 来自山西省

    认真学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2228053, encodeId=d0452228053d7, content=预后极差,在美国统计的所有癌症中,胰腺癌的5年生存率最低(12%), beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0ad1894147, createdName=ms1907128386112981, createdTime=Fri Sep 27 21:39:13 CST 2024, time=2024-09-27, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2228046, encodeId=8090222804644, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Sep 27 20:58:00 CST 2024, time=2024-09-27, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2228066, encodeId=662922280668f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Sep 27 22:43:23 CST 2024, time=2024-09-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2228063, encodeId=0cfc222806344, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Fri Sep 27 22:15:46 CST 2024, time=2024-09-27, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2228095, encodeId=1221222809552, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Fri Sep 27 23:54:40 CST 2024, time=2024-09-27, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2228015, encodeId=378c2228015ae, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a> <a href='/topic/show?id=d524119613d4' target=_blank style='color:#2F92EE;'>#胰管闭塞#</a> <a href='/topic/show?id=c03511961492' target=_blank style='color:#2F92EE;'>#术后转归#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=119614, encryptionId=c03511961492, topicName=术后转归), TopicDto(id=119613, encryptionId=d524119613d4, topicName=胰管闭塞), TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cade5395722, createdName=梅斯管理员, createdTime=Fri Sep 27 16:24:58 CST 2024, time=2024-09-27, status=1, ipAttribution=上海)]
    2024-09-27 1209e435m98(暂无昵称) 来自浙江省

    学习了,谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2228053, encodeId=d0452228053d7, content=预后极差,在美国统计的所有癌症中,胰腺癌的5年生存率最低(12%), beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0ad1894147, createdName=ms1907128386112981, createdTime=Fri Sep 27 21:39:13 CST 2024, time=2024-09-27, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2228046, encodeId=8090222804644, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Sep 27 20:58:00 CST 2024, time=2024-09-27, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2228066, encodeId=662922280668f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Sep 27 22:43:23 CST 2024, time=2024-09-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2228063, encodeId=0cfc222806344, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Fri Sep 27 22:15:46 CST 2024, time=2024-09-27, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2228095, encodeId=1221222809552, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Fri Sep 27 23:54:40 CST 2024, time=2024-09-27, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2228015, encodeId=378c2228015ae, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a> <a href='/topic/show?id=d524119613d4' target=_blank style='color:#2F92EE;'>#胰管闭塞#</a> <a href='/topic/show?id=c03511961492' target=_blank style='color:#2F92EE;'>#术后转归#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=119614, encryptionId=c03511961492, topicName=术后转归), TopicDto(id=119613, encryptionId=d524119613d4, topicName=胰管闭塞), TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cade5395722, createdName=梅斯管理员, createdTime=Fri Sep 27 16:24:58 CST 2024, time=2024-09-27, status=1, ipAttribution=上海)]
    2024-09-27 仁术2021 来自吉林省

    不错,学习了。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2228053, encodeId=d0452228053d7, content=预后极差,在美国统计的所有癌症中,胰腺癌的5年生存率最低(12%), beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0ad1894147, createdName=ms1907128386112981, createdTime=Fri Sep 27 21:39:13 CST 2024, time=2024-09-27, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2228046, encodeId=8090222804644, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Sep 27 20:58:00 CST 2024, time=2024-09-27, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2228066, encodeId=662922280668f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Sep 27 22:43:23 CST 2024, time=2024-09-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2228063, encodeId=0cfc222806344, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Fri Sep 27 22:15:46 CST 2024, time=2024-09-27, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2228095, encodeId=1221222809552, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Fri Sep 27 23:54:40 CST 2024, time=2024-09-27, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2228015, encodeId=378c2228015ae, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a> <a href='/topic/show?id=d524119613d4' target=_blank style='color:#2F92EE;'>#胰管闭塞#</a> <a href='/topic/show?id=c03511961492' target=_blank style='color:#2F92EE;'>#术后转归#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=119614, encryptionId=c03511961492, topicName=术后转归), TopicDto(id=119613, encryptionId=d524119613d4, topicName=胰管闭塞), TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cade5395722, createdName=梅斯管理员, createdTime=Fri Sep 27 16:24:58 CST 2024, time=2024-09-27, status=1, ipAttribution=上海)]
    2024-09-27 屋顶瞄爱赏月 来自贵州省

    签到学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2228053, encodeId=d0452228053d7, content=预后极差,在美国统计的所有癌症中,胰腺癌的5年生存率最低(12%), beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e0ad1894147, createdName=ms1907128386112981, createdTime=Fri Sep 27 21:39:13 CST 2024, time=2024-09-27, status=1, ipAttribution=河北省), GetPortalCommentsPageByObjectIdResponse(id=2228046, encodeId=8090222804644, content=认真学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6EF3hKja8nER8RMzxQdria9eCYFhgLTLsDOeqnvIYdeLDz5eP6EnicLuE5gibiawgno4zUA0jAR7Nbtp2llQ9fs3Mk/0, createdBy=278f1986883, createdName=医鸣惊人, createdTime=Fri Sep 27 20:58:00 CST 2024, time=2024-09-27, status=1, ipAttribution=山西省), GetPortalCommentsPageByObjectIdResponse(id=2228066, encodeId=662922280668f, content=学习了,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Fri Sep 27 22:43:23 CST 2024, time=2024-09-27, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2228063, encodeId=0cfc222806344, content=不错,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210606/e8b96fdba070433da10cd357c0646807/28bf16f46e314caaad8396c0c7df7a04.jpg, createdBy=adb15496357, createdName=仁术2021, createdTime=Fri Sep 27 22:15:46 CST 2024, time=2024-09-27, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2228095, encodeId=1221222809552, content=签到学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Fri Sep 27 23:54:40 CST 2024, time=2024-09-27, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2228015, encodeId=378c2228015ae, content=<a href='/topic/show?id=04b5839e6a9' target=_blank style='color:#2F92EE;'>#胰腺癌#</a> <a href='/topic/show?id=d524119613d4' target=_blank style='color:#2F92EE;'>#胰管闭塞#</a> <a href='/topic/show?id=c03511961492' target=_blank style='color:#2F92EE;'>#术后转归#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=119614, encryptionId=c03511961492, topicName=术后转归), TopicDto(id=119613, encryptionId=d524119613d4, topicName=胰管闭塞), TopicDto(id=83976, encryptionId=04b5839e6a9, topicName=胰腺癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cade5395722, createdName=梅斯管理员, createdTime=Fri Sep 27 16:24:58 CST 2024, time=2024-09-27, status=1, ipAttribution=上海)]

相关资讯

【协和医学杂志】胰腺癌多学科协作诊疗模式的发展及协和经验

本文从我国胰腺癌MDT诊疗模式的起源、发展现状、存在不足展开论述,并对未来发展进行展望,以期为我国MDT诊疗的建设提供参考。

【协和医学杂志】全胰切除术与胰十二指肠切除术治疗胰腺癌的手术疗效和生活质量对比分析:基于倾向性评分匹配的回顾性队列研究

本研究旨在比较接受上述两种术式的胰腺癌患者在术后并发症、短期死亡率、长期生活质量及生存期方面的差异,以期为TP的临床应用积累更多循证医学证据,同时为胰腺癌患者最佳手术策略的制订提供参考。

【协和医学杂志】磁-光多模态分子影像在胰腺癌精准诊疗中的应用进展

本文将聚焦磁-光多模态分子影像在胰腺癌精准诊疗中的应用进展,探讨其现状并展望未来发展方向。

欺骗免疫系统攻击“伪装的肿瘤”,临床前模型88%的胰腺癌病灶萎缩或消失!

为了解决免疫治疗胰腺癌的问题,科学家想到了使用其他的药物来激活肿瘤微环境,通过一种新型纳米颗粒药物输送系统和肿瘤靶向药结合,来激活免疫微环境。

【协和医学杂志】胰腺癌相关疼痛的诊疗现状

本文就胰腺癌相关疼痛的病理生理机制及治疗策略进行综述,以期为胰腺癌临床镇痛实践提供参考。 

【衡道丨干货】2024版CSCO胰腺癌指南更新,国内外权威共识指南中的胰腺癌的病理诊断有何异同?

本文通过与NCCN胰腺癌指南对比,对2024版CSCO胰腺癌指南中的病理诊断部分内容进行了汇总介绍。

OCR 2024 | 专访边云教授:从CT平扫到多模态融合,人工智能助力胰腺癌影像学诊断开启新篇章

梅斯医学紧跟学术前沿,特邀边云教授深度解读了多种影像技术在胰腺癌诊断中的应用,并展望胰腺癌影像学未来发展趋势。

【协和医学杂志】ERCP与EUS-FNA融合技术对胰腺癌合并梗阻性黄疸的诊治效能

,本研究通过回顾性分析,探讨EUS-FNA和ERCP融合技术在胰腺癌合并梗阻性黄疸患者诊治中的作用。

Cancer Res:中国医学科学院张太平团队揭示了FBXO32刺激蛋白合成驱动胰腺癌进展和转移

该研究发现FBXO32是PDAC的致癌驱动因子。FBXO32在PDAC中异常上调,高水平的FBXO32表达与PDAC患者不良预后显著相关。

挑战癌王,三药联用方案实现了95.5%的疾病控制率,一半患者实现了部分缓解!

胰腺癌发病率和死亡率上升,现有化疗方案效果有限。介绍三类药物组合在胰腺癌的临床研究,PAAG 方案显示良好疗效但有不良反应。